Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
- Plasma cell myeloma is a type of cancer that affects the plasma cells in the bone marrow. It can be difficult to treat with chemotherapy. One possible treatment combines chemotherapy with a stem cell transplant. To make this treatment more effective, researchers want to give another drug along with the transplant. This drug, carfilzomib, is often used to help treat plasma cell myeloma. However, it is not usually given along with the transplant. Researchers want to see if it is safe and effective to combine the stem cell transplant with carfilzomib, and if it improves the results of the transplant.
- To test the safety and effectiveness of carfilzomib given with stem cell transplant for plasma cell myeloma.
- Individuals between 18 and 75 years of age who are having a stem cell transplant to treat plasma cell myeloma.
- Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and a bone marrow biopsy will also be performed.
- Participants will have their own stem cells collected for the transplant. The transplant will be performed according to the standard of care.
- All participants will receive carfilzomib on the first 2 days after transplant. The study doctors will determine the number of additional doses that they may have.
- Treatment will be monitored with frequent blood tests and imaging studies.
Leukemia, Plasma Cell
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma|
- Engraftment failure transplant related mortality
- Response rate at day 100 post-AHCT
|Study Start Date:||July 2012|
|Estimated Study Completion Date:||June 2017|
|Estimated Primary Completion Date:||June 2017 (Final data collection date for primary outcome measure)|
- Despite very significant progress in therapy for plasma cell myeloma (PCM) in the last decade, the disease remains mostly incurable.
- High-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT) continues to be a critical component of early treatment for PCM, but it is clear that the disease is not eradicated by the present high-dose therapy strategy, while intensifying the preparative regimen has, to this day, resulted in either no improvement in disease control or increased toxicity.
- Carfilzomib (CFZ) is a newer proteasome inhibitor with increased activity and a safer toxicity profile than bortezomib in PCM. The favorable toxicity profile makes it a likely candidate for increasing anti-PCM drug exposure in the early post-AHCT period.
-Evaluate feasibility and toxicity of an increasing number of doses of CFZ administered in the early period post-AHCT for PCM
- Evaluate the immune reconstitution post-AHCT following CFZ therapy
- Evaluate the effects of the addition of CFZ in the early post-AHCT period on the response rate at day 100 post-AHCT
- Newly diagnosed subjects with PCM following induction therapy
- Subjects with documentation of persistent/refractory disease who have received no more than 2 salvage regimens following relapse and who have not undergone AHCT
- Adequate organ functions with no major co-morbidity
- Age greater than 18 years and less than or equal to 75 years
- Phase I/II study on the backbone of high-dose melphalan on day -2 pre-AHCT
- Addition of an increasing number of doses of CFZ in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m2 on days +1, +2
Cohort 2 : add CFZ 20 mg/m2 on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m2 on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following
engraftment: CFZ 20 mg/m2 given on days 42-43 then CFZ 56 mg/m2 given on days 49-50, 56-57, then on days 70-71, 77-78 and 84-85
-Dose-limiting toxicity, incidence of engraftment failure and treatment-related mortality are the objects of early stopping rules for safety purposes
|Contact: Candice M Cottle-Delisle, R.N.||(301) email@example.com|
|Contact: Claude Sportes, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937|
|Principal Investigator:||Claude Sportes, M.D.||National Cancer Institute (NCI)|